Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01 2022 - 4:01PM
Business Wire
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the
development of medicines that control the expression of genes,
today announced the grant of restricted stock unit (RSU) awards for
an aggregate of 89,400 shares of Syros common stock to three newly
hired employees in connection with their commencement of employment
with Syros. These RSUs were granted as material inducements to
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted on March 31, 2022, vest as to one-quarter
of the shares on each of the first four anniversaries of the grant
date subject to the employee’s continued service with Syros, and
are subject to the terms and conditions of a restricted stock unit
agreement covering the award and Syros’ 2022 Inducement Stock
Incentive Plan.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors and blood cancers. Syros also has multiple preclinical
and discovery programs in oncology and monogenic diseases. For more
information, visit www.syros.com and follow us on Twitter
(@SyrosPharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220401005059/en/
Media: Courtney Solberg Syros Pharmaceuticals 917-698-9253
csolberg@syros.com
Investors: Hannah Deresiewicz Stern Investor Relations, Inc.
212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024